# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Merck's rVSV-ZEBOV vaccine, the only WHO-prequalified vaccine for Ebola outbreaks caused by the Zaire ebolavirus, is FDA-ap...
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims ...
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood...
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or ref...